For decades, prostate cancer treatment has largely been described by where the cancer is located and how far it has spread. Today, physicians can also look at something much more specific: what is happening on the surface of the cancer cell itself.
One important target is PSMA, or prostate-specific membrane antigen.
PSMA is a protein commonly found at high levels on prostate cancer cells. It has become an important target not only for finding prostate cancer with molecular imaging, but also for delivering treatment directly to PSMA-positive cancer cells.
That is where Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) comes in.
And yes, the full generic name is quite a mouthful. Fortunately, understanding the basic idea behind the treatment is much easier.
What Is Pluvicto?
Pluvicto is a PSMA-targeted radioligand therapy used for certain patients with PSMA-positive metastatic prostate cancer.
Rather than delivering radiation from a machine outside the body, Pluvicto is administered intravenously and travels through the bloodstream.
The treatment consists of a molecule designed to recognize and bind to PSMA attached to the radioactive isotope lutetium-177 (Lu-177).
Once Pluvicto binds to PSMA-positive cells, radiation from Lu-177 damages the targeted cells as well as nearby cells.
In other words, the same biological characteristic that can help physicians find prostate cancer can also become a way to target it with treatment.
Why Is PSMA So Important?
PSMA stands for prostate-specific membrane antigen. It is a transmembrane protein that is frequently expressed at higher levels by prostate cancer cells.
This makes PSMA particularly useful in nuclear medicine because physicians can use specially designed radiopharmaceuticals that seek out this target.
For imaging, a PSMA-targeted radiotracer can be used with PET imaging to identify areas of PSMA expression throughout the body.
For therapy, Pluvicto uses a PSMA-targeting molecule to carry Lu-177 to PSMA-positive cancer cells.
Think of PSMA less like an address and more like a molecular marker that physicians can look for.
PSMA PET: Finding the Target Before Treatment
Not every prostate cancer patient is automatically a candidate for Pluvicto.
PSMA PET imaging plays an important role in patient selection.
Before receiving Pluvicto, patients are evaluated with an FDA-approved PSMA PET imaging agent to determine whether their tumors demonstrate appropriate PSMA expression.
The scan uses a PSMA-targeted radiotracer. Areas expressing PSMA can then be visualized on PET imaging, giving the care team information about the location and extent of PSMA-positive disease.
The FDA specifically requires patient selection for Pluvicto based on PSMA expression using an approved PSMA PET product.
This connection between molecular imaging and targeted therapy is one of the clearest examples of theranostics in modern cancer care.
What Is Theranostics?
The word theranostics combines two concepts:
Therapy + Diagnostics
The basic principle is straightforward.
First, molecular imaging identifies a biological target associated with a patient’s cancer.
Then, when appropriate, a therapeutic radiopharmaceutical uses that same target to deliver treatment.
With PSMA-positive prostate cancer, physicians can use PSMA PET imaging to identify the target and determine whether a patient may be eligible for PSMA-directed radioligand therapy.
It represents an important shift toward treatment based not only on the location of a tumor, but also on its molecular characteristics.
Who May Be Eligible for Pluvicto?
The approved use of Pluvicto has expanded considerably since its original FDA approval in 2022.
In March 2025, the FDA expanded Pluvicto’s indication to adults with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have received androgen receptor pathway inhibitor (ARPI) therapy and either are considered appropriate to delay taxane-based chemotherapy or have previously received taxane chemotherapy.
Then, in July 2026, the FDA approved Pluvicto in combination with ARPI therapy for adults with PSMA-positive metastatic androgen pathway modulation-naïve or -sensitive prostate cancer, commonly referred to as metastatic hormone-sensitive prostate cancer.
These approvals mean PSMA-targeted radioligand therapy can now play a role at different stages of metastatic prostate cancer.
Eligibility remains highly individualized. A patient’s oncologist considers the type and stage of prostate cancer, previous and current therapies, PSMA PET findings, overall health and other clinical factors before determining whether Pluvicto is appropriate.
What Happens During Pluvicto Treatment?
Pluvicto is administered intravenously at a healthcare facility equipped to provide radiopharmaceutical therapy.
The exact treatment plan depends on the patient’s clinical situation and current prescribing information. Treatment also involves laboratory monitoring because Pluvicto can affect blood cell counts and kidney function.
Because Pluvicto contains radioactive material, patients receive radiation-safety instructions to follow after treatment.
Hydration is also important. Current prescribing information advises patients to increase oral fluid intake and urinate frequently to help reduce radiation exposure to the bladder.
So while the science behind Pluvicto involves nuclear physics, molecular biology and oncology, the patient experience includes some very familiar instructions: drink your water.
What Are the Potential Risks of Pluvicto?
Like any cancer therapy, Pluvicto has potential risks and side effects.
Important risks identified in prescribing information include radiation exposure, myelosuppression (decreased blood cell counts), kidney toxicity and embryo-fetal toxicity.
Patients should discuss the potential benefits and risks with their oncology team and follow all laboratory monitoring, hydration and radiation-safety instructions provided by their healthcare professionals.
Pluvicto is not appropriate for every patient with prostate cancer, and treatment decisions should always be individualized.
Why Specialized Radiopharmaceutical Therapy Matters
Radiopharmaceutical therapy brings together several highly specialized areas of medicine.
Treatment requires appropriate patient selection, radioactive-material handling, radiation-safety procedures, treatment administration and ongoing coordination with the patient’s oncology team.
For patients and families, having an experienced team can also make an unfamiliar form of cancer treatment easier to navigate.
Terms such as PSMA, Lu-177, radioligand therapy and theranostics may sound complicated at first.
The goal of the care team should be to make the process itself much clearer.
Pluvicto Treatment at Excel Diagnostics & Nuclear Oncology Center
At Excel Diagnostics & Nuclear Oncology Center in Houston, Texas, advanced molecular imaging and radiopharmaceutical therapy are part of a connected approach to cancer care.
Excel provides specialized services for patients with prostate cancer, including PSMA PET imaging and Pluvicto radiopharmaceutical therapy.
Our team works alongside referring oncologists and other healthcare providers to help coordinate imaging, patient evaluation, treatment and follow-up.
For patients, that means the journey from identifying a molecular target to receiving targeted radiopharmaceutical therapy can be supported by a team experienced in nuclear medicine and theranostics.
At Excel, sophisticated technology is only part of the equation. We believe patients and their families should also understand what is happening, why it is happening and what to expect next.
Looking for Pluvicto Treatment in Houston?
If you or someone you care for has metastatic prostate cancer and would like to learn more about PSMA PET imaging or Pluvicto treatment in Houston, speak with your oncologist about whether PSMA-targeted imaging and therapy may be appropriate.
Patients and referring physicians can also contact Excel Diagnostics & Nuclear Oncology Center for information about referrals, PSMA PET imaging, Pluvicto treatment and scheduling.
Excel Diagnostics & Nuclear Oncology Center
Houston, Texas
This article is for educational purposes only and does not provide medical advice or determine eligibility for Pluvicto. Treatment decisions should be made by the patient and their qualified healthcare professionals based on the patient’s individual medical circumstances and current FDA-approved prescribing information.